Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Upstream binding transcription factor, RNA polymerase I-like 10 (pseudogene), abbreviated as UBTFL10, is a pseudogene in the human genome. As a pseudogene, it is unlikely to produce a functional protein and is not considered a therapeutic target. Pseudogenes are genomic elements that resemble known genes but, due to mutations, do not function as protein-coding genes or have lost their original biological function. There is no evidence that UBTFL10 directly influences biological processes, disease processes, or drug responses. It is classified as a member of the upstream binding transcription factor-like family, but its status as a pseudogene removes it from consideration as a receptor, enzyme, transporter, or transcription factor in the context of drug discovery or therapeutic development[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Upstream binding transcription factor, RNA polymerase I-like 10 (pseudogene) (UBTFL10).